Drug reference

Erenumab

Monoclonal Antibody · Migraine Prophylaxis

Also known as Aimovig

Monoclonal AntibodyMigraine Prophylaxis

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Manufacturer advises avoid—limited information available.

FDA category + note

Mechanism

Erenumab is an anti-CGRP (Calcitonin Gene-Related Peptide) agent. It works by blocking the activity of CGRP, a neuropeptide involved in nociceptive transmission and the pathophysiology of migraine. By inhibiting CGRP signaling, erenumab helps to prevent migraine attacks.

Indications

Prophylaxis of migraine in adults who have at least four migraine days per month and in whom at least three prior prophylactic treatments have failed

Dosing

Adult: Initially 70 mg every 4 weeks; increased if necessary to 140 mg every 4 weeks. Consider discontinuing if no response after 3 months of treatment.
Max dose: 140 mg every 4 weeks

Side effects

Common

ConstipationMuscle spasmsSkin reactions

Serious

Oedema
Swelling

Pregnancy & lactation

Pregnancy

Manufacturer advises avoid—limited information available.

Lactation

Manufacturer advises avoid during first few days after birth—possible risk from transfer of antibodies to infant. After this time, use during breastfeeding only if clinically needed.